Kisspeptin and Neurokinin B: From Reproductive Brain Science to New Fertility and Menopause Treatments
Kisspeptin and neurokinin B — two neuropeptides that control reproduction — are being translated into clinical therapies for infertility, menopause symptoms, endometriosis, and uterine fibroids.
Quick Facts
What This Study Found
Kisspeptin has been established as the master regulator of mammalian reproduction, controlling both puberty onset and ongoing fertility. Human studies confirm that kisspeptin administration stimulates physiological reproductive hormone secretion in healthy men and women, as well as in patients with common reproductive disorders.
Neurokinin B (NKB), which works alongside kisspeptin in KNDy neurons (kisspeptin/neurokinin B/dynorphin neurons), has emerged as a therapeutic target for menopausal hot flashes, endometriosis, and uterine fibroids. NKB receptor antagonists are being developed as treatments for these conditions. Together, kisspeptin and NKB represent two complementary peptide-based approaches to managing reproductive health.
Key Numbers
How They Did This
This is an invited narrative review synthesizing evidence from animal models, human physiological studies, and clinical trials involving kisspeptin and neurokinin B in reproductive health contexts.
Why This Research Matters
Current fertility treatments rely heavily on synthetic GnRH analogs and gonadotropin injections, which can cause side effects like ovarian hyperstimulation syndrome. Kisspeptin offers a more physiological alternative that stimulates the body's own hormone cascade. Meanwhile, NKB antagonists are already reaching late-stage clinical trials for menopause symptoms and gynecological conditions, positioning these reproductive neuropeptides as the basis for an entirely new class of therapies.
The Bigger Picture
The discovery of kisspeptin's role in reproduction (around 2003) reshaped reproductive endocrinology. NKB antagonists like fezolinetant have since reached clinical approval for menopausal vasomotor symptoms, validating the therapeutic potential of targeting the KNDy neuron system. Kisspeptin-based IVF triggers are being studied as safer alternatives to hCG, which can cause dangerous ovarian hyperstimulation. This review captures a pivotal moment when basic neuropeptide science is becoming real clinical medicine.
What This Study Doesn't Tell Us
As a narrative review, this paper summarizes and interprets existing evidence rather than presenting new experimental data. The review focuses on kisspeptin and NKB while noting that dynorphin (the third KNDy peptide) also plays important roles that are less therapeutically developed. Some of the clinical applications discussed were still in early-stage trials at the time of writing.
Questions This Raises
- ?Can kisspeptin replace hCG as the standard ovulation trigger in IVF, and would it meaningfully reduce ovarian hyperstimulation syndrome?
- ?Will NKB antagonists prove effective long-term for endometriosis and fibroids, or will they primarily serve as symptom management?
- ?What role does dynorphin — the third KNDy peptide — play therapeutically, and could targeting it add clinical value?
Trust & Context
- Key Stat:
- Master regulator of reproduction Kisspeptin controls both puberty onset and adult fertility, and human studies confirm it can stimulate reproductive hormones in healthy people and patients with disorders
- Evidence Grade:
- This is an invited review article synthesizing evidence from animal studies, human physiological experiments, and clinical trials. It provides a comprehensive overview rather than new primary data, but the reviewed evidence includes human clinical studies.
- Study Age:
- Published in 2022, this review captures the state of kisspeptin and NKB therapeutics development. Since then, NKB antagonists like fezolinetant have gained regulatory approval, validating the therapeutic direction described here.
- Original Title:
- Invited review: Translating kisspeptin and neurokinin B biology into new therapies for reproductive health.
- Published In:
- Journal of neuroendocrinology, 34(10), e13201 (2022)
- Authors:
- Mills, Edouard G(2), Dhillo, Waljit S(8)
- Database ID:
- RPEP-06371
Evidence Hierarchy
Frequently Asked Questions
What is kisspeptin and why does it matter for fertility?
Kisspeptin is a brain peptide that acts as the master switch for reproduction. It triggers GnRH release, which in turn drives the hormones (LH and FSH) that control ovulation, sperm production, and puberty. Without functioning kisspeptin signaling, puberty doesn't start and fertility is impaired. Researchers are now using kisspeptin injections as a more natural way to trigger ovulation in IVF.
How are neurokinin B blockers being used for menopause?
Neurokinin B (NKB) helps regulate body temperature through the same brain neurons that control reproduction. During menopause, when estrogen drops, NKB signaling goes haywire and triggers hot flashes. NKB receptor antagonists block this overactive signaling, reducing hot flashes without using hormone replacement therapy. Fezolinetant is an example that has reached clinical use.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06371APA
Mills, Edouard G; Dhillo, Waljit S. (2022). Invited review: Translating kisspeptin and neurokinin B biology into new therapies for reproductive health.. Journal of neuroendocrinology, 34(10), e13201. https://doi.org/10.1111/jne.13201
MLA
Mills, Edouard G, et al. "Invited review: Translating kisspeptin and neurokinin B biology into new therapies for reproductive health.." Journal of neuroendocrinology, 2022. https://doi.org/10.1111/jne.13201
RethinkPeptides
RethinkPeptides Research Database. "Invited review: Translating kisspeptin and neurokinin B biol..." RPEP-06371. Retrieved from https://rethinkpeptides.com/research/mills-2022-invited-review-translating-kisspeptin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.